FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2987262117> ?p ?o ?g. }

• W2987262117 endingPage "4183" @default.
• W2987262117 startingPage "4183" @default.
• W2987262117 abstract "Introduction Myeloproliferative neoplasms (MPN) are associated with an increased rate of venous thromboembolism (VTE), which can be a major cause of morbidity and mortality especially in the more indolent diseases of polycythaemia rubra vera (PV) and essential thrombocythaemia (ET). Splanchnic vein thromboses are common in MPN and may have high recurrence rates between 15-20% over 10 years1. Traditionally, vitamin K antagonists (VKA) have been the mainstay of anticoagulation for MPN-associated VTE and recent data suggests a high rate of recurrent VTE on their discontinuation in MPN patients2. In the last 5 years, there has been a significant change to the use of direct oral anticoagulants (DOAC) in non-MPN associated VTE and limited data is available in the MPN setting due to the exclusion of malignancies from initial Phase III studies. Methods A retrospective review of patients treated at a single tertiary centre for MPN was performed. Clinical details were obtained from electronic clinical notes, imaging and prescriptions. Results A total of 102 patients were identified as having a MPN-associated VTE with 24 of these receiving DOACs. The median age at VTE was 48 years (range 27.4-92.2 years) with 10 males (41.7%), primary diagnosis: 10 PV, 5 ET, 7 myelofibrosis (MF) and 2 MPN/myelodysplasia overlap. 18 patients were JAK2 V617F positive, 1 pt had MPL mutation and 5 pts were triple negative. In total 29 thrombotic events were recorded - 10 splanchnic (34.4%), 10 pulmonary embolism (34.4%), 5 deep vein thrombosis (17.2%), 2 cerebral venous sinus thrombosis (6.9%), 1 superficial thrombophlebitis (3.4%). The median follow-up period was 2.2 years (range 0.7-7.5 years) with 16 patients initiated on DOAC (12 rivaroxaban and 4 apixaban) and 8 patients changed from VKA or heparin (3 rivaroxaban, 3 apixaban and 1 edoxaban). Two patients used more than one DOAC in this period. 21 patients were receiving long-term anticoagulation and 3 had defined courses of anticoagulation due to provocation. 21 patients were receiving cytoreductive agents or regular venesection along with anticoagulation. During the total follow-up period of patients receiving DOACs, amounting to 66 pt years, there were no VTE recurrences in 23 patients and indeterminate imaging for 1. There were no episodes of major bleeding but 2 patients (8.3%) had clinically relevant non-major bleeding both of which were taking aspirin in addition to DOAC. Conclusions These results suggest that there were very low/no recurrence rates of VTE and no major bleeding in patients with MPN-associated VTE who are receiving DOACs. These include heterogeneous sites of VTE including splanchnic vein thromboses and cerebral venous sinus thrombosis. Of note, cytoreductive measures were also used in a majority of these patients. We suggest that DOACs could be safely used in this group in appropriately selected patients with MPN. References: 1. Finazzi G, De Stefano V, Barbui T. Splanchnic vein thrombosis in myeloproliferative neoplasms: treatment algorithm. Blood Cancer J. 2018; 8(7): 64. 2. De Stefano V, Ruggeri M, Cervantes F et al. High rate of recurrent venous thromboembolism in patients with myeloproliferative neoplasms and effect of prophylaxis with vitamin K antagonists. Leukemia. 2016; 30(10): 2032-38. Table Disclosures McLornan: Jazz Pharmaceuticals: Honoraria, Speakers Bureau; Novartis: Honoraria. Radia:Blueprint Medicines: Consultancy; Novartis: Consultancy, Speakers Bureau. Harrison:AOP: Honoraria; Promedior: Honoraria; Gilead: Speakers Bureau; Roche: Honoraria; Janssen: Speakers Bureau; Celgene: Honoraria, Speakers Bureau; Sierra Oncology: Honoraria; CTI: Speakers Bureau; Novartis: Honoraria, Research Funding, Speakers Bureau; Shire: Speakers Bureau; Incyte: Speakers Bureau." @default.
• W2987262117 created "2019-11-22" @default.
• W2987262117 creator A5007031740 @default.
• W2987262117 creator A5017537622 @default.
• W2987262117 creator A5028061272 @default.
• W2987262117 creator A5032411762 @default.
• W2987262117 creator A5046827092 @default.
• W2987262117 creator A5048076310 @default.
• W2987262117 creator A5054364258 @default.
• W2987262117 creator A5087261151 @default.
• W2987262117 date "2019-11-13" @default.
• W2987262117 modified "2023-09-27" @default.
• W2987262117 title "Outcomes of Patients Receiving Direct Oral Anticoagulants for Myeloproliferative Neoplasm Associated Venous Thromboembolism" @default.
• W2987262117 doi "https://doi.org/10.1182/blood-2019-128170" @default.
• W2987262117 hasPublicationYear "2019" @default.
• W2987262117 type Work @default.
• W2987262117 sameAs 2987262117 @default.
• W2987262117 citedByCount "1" @default.
• W2987262117 countsByYear W29872621172021 @default.
• W2987262117 crossrefType "journal-article" @default.
• W2987262117 hasAuthorship W2987262117A5007031740 @default.
• W2987262117 hasAuthorship W2987262117A5017537622 @default.
• W2987262117 hasAuthorship W2987262117A5028061272 @default.
• W2987262117 hasAuthorship W2987262117A5032411762 @default.
• W2987262117 hasAuthorship W2987262117A5046827092 @default.
• W2987262117 hasAuthorship W2987262117A5048076310 @default.
• W2987262117 hasAuthorship W2987262117A5054364258 @default.
• W2987262117 hasAuthorship W2987262117A5087261151 @default.
• W2987262117 hasConcept C126322002 @default.
• W2987262117 hasConcept C141071460 @default.
• W2987262117 hasConcept C2776265017 @default.
• W2987262117 hasConcept C2778715236 @default.
• W2987262117 hasConcept C2778837598 @default.
• W2987262117 hasConcept C2780007613 @default.
• W2987262117 hasConcept C2780011451 @default.
• W2987262117 hasConcept C2780076729 @default.
• W2987262117 hasConcept C2780868729 @default.
• W2987262117 hasConcept C2781107747 @default.
• W2987262117 hasConcept C71924100 @default.
• W2987262117 hasConcept C90924648 @default.
• W2987262117 hasConceptScore W2987262117C126322002 @default.
• W2987262117 hasConceptScore W2987262117C141071460 @default.
• W2987262117 hasConceptScore W2987262117C2776265017 @default.
• W2987262117 hasConceptScore W2987262117C2778715236 @default.
• W2987262117 hasConceptScore W2987262117C2778837598 @default.
• W2987262117 hasConceptScore W2987262117C2780007613 @default.
• W2987262117 hasConceptScore W2987262117C2780011451 @default.
• W2987262117 hasConceptScore W2987262117C2780076729 @default.
• W2987262117 hasConceptScore W2987262117C2780868729 @default.
• W2987262117 hasConceptScore W2987262117C2781107747 @default.
• W2987262117 hasConceptScore W2987262117C71924100 @default.
• W2987262117 hasConceptScore W2987262117C90924648 @default.
• W2987262117 hasIssue "Supplement_1" @default.
• W2987262117 hasLocation W29872621171 @default.
• W2987262117 hasOpenAccess W2987262117 @default.
• W2987262117 hasPrimaryLocation W29872621171 @default.
• W2987262117 hasRelatedWork W2004210966 @default.
• W2987262117 hasRelatedWork W2129148152 @default.
• W2987262117 hasRelatedWork W2314663195 @default.
• W2987262117 hasRelatedWork W2316089822 @default.
• W2987262117 hasRelatedWork W2371372815 @default.
• W2987262117 hasRelatedWork W2903749170 @default.
• W2987262117 hasRelatedWork W2946211350 @default.
• W2987262117 hasRelatedWork W3186733414 @default.
• W2987262117 hasRelatedWork W3217566414 @default.
• W2987262117 hasRelatedWork W4288367276 @default.
• W2987262117 hasVolume "134" @default.
• W2987262117 isParatext "false" @default.
• W2987262117 isRetracted "false" @default.
• W2987262117 magId "2987262117" @default.
• W2987262117 workType "article" @default.